

Ruxandra Maria Irimia

LinkedIn: <https://www.linkedin.com/in/ruxandra-irimia-816b0620a>

ResearchGate: <https://www.researchgate.net/profile/Ruxandra-Irimia>

Professional Experience

Hematology Specialist

February 2023- July 2024

Fundeni Clinical Institute, Hematology and Bone Marrow Transplant Department,
Bucharest, Romania

Responsibilities: Perform clinical activity with a focus on hematologic malignancies

Assistant lecturer

January 2022 – July 2024

“Carol Davila” University of Medicine and Pharmacy- Bucharest, Romania

Responsibilities: Conduct hematology seminars and lectures for medical students

Resident Physician- Clinical Hematology

January 2022-January 2023

Fundeni Clinical Institute, Hematology and Bone Marrow Transplant Department,
Bucharest, Romania

Responsibilities: Perform clinical activity in hematology under the supervision of a senior attending, focusing on both malignant and benign conditions

Oncology Trainee

January 2021-December 2021

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore
Maryland, USA

Responsibilities: Conduct translational research focusing on the role of CD38 in
Multiple Myeloma, covering disease biology, metabolism, microenvironment and
targeted therapeutics

Achievements: Awarded the ASH Abstract Achievement Award 2021 for the poster
“CD38 is a key regulator of tumor growth by modulating the metabolic signature of
malignant plasma cells”

Resident Physician- Clinical Hematology

January 2017-December 2021

Fundeni Clinical Institute, Hematology and Bone Marrow Transplant Department,
Bucharest, Romania

Responsibilities: Perform clinical activity in hematology under the supervision of a senior attending, focusing on both malignant and benign conditions

**Education and
qualifications**

Master in Public Health candidate

Sommer scholar

July 2024 - present

Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

Clinical observership

July 2024 – December 2024

Benign hematology - autoimmune hematologic disorders, endothelial injury syndromes and thrombotic disorders

Johns Hopkins Hospital, Baltimore, Maryland, USA

Clinical observership

November 2024

Malignant hematology - plasma cell dyscrasias

Dana Farber Cancer Center, Boston, Massachusetts, USA

PhD candidate

October 2020– present

“Carol Davila” University of Medicine and Pharmacy- Bucharest, Romania

Thesis: Biologic factors influencing clinical evolution and treatment response in Multiple Myeloma

Medical Student

2010-2016

“Carol Davila” University of Medicine and Pharmacy-Bucharest, Romania

Medical student

October 2014-February 2015

Universita di Bologna, Scuola di Medicina e Chirurgia, Bologna, Italy

Certifications

Clinical Research Training in Hematology (EHA)

2023

Intensive mentoring and educational initiative designed to equip early-career hematologists with essential skills to conduct high-quality clinical research

European Hematology Exam

2022

Standardized assessment of knowledge and competencies in hematology, aligning with European standards for clinical practice and education

Research Experience

Oncology trainee

January 2021-December 2021

PI: Christian B. Gocke - cgocke2@jhmi.edu

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University Baltimore, Maryland, USA

Responsibilities: Conduct translational research focusing on the role of CD38 in Multiple Myeloma, covering disease biology, metabolism, microenvironment and targeted therapeutics

Visitor trainee

November 2019 – February 2020

PI: Gabriel Ghiaur - gghiaur1@jhmi.edu

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University Baltimore, Maryland, USA

Responsibilities: Conduct translational research focusing on the role of retinoids in proteasome-inhibitor sensitivity restoration in Multiple Myeloma

Research Assistant

2010-2015

PI: Irina Baran - irina.baran@umfcd.ro

Biophysics Department, Carol Davila University of Medicine and Pharmacy

Responsibilities: Conduct basic research focusing on ATLL - mechanistic insights in the disease biology and targeted therapies

Clinical trial experience

CANDOR - A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
NCT03158688

Co-investigator

Supervising patient recruitment, enrollment, and informed consent processes; monitoring treatment – administration, safety and adverse event management and reporting; data collection and interpretation

ARROW2 - A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma NCT03859427

Co-investigator

Supervising patient recruitment, enrollment, and informed consent processes; monitoring treatment – administration, safety and adverse event management and reporting; data collection and interpretation

OCEAN - a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma NCT03151811

Co-investigator

Supervising patient recruitment, enrollment, and informed consent processes; monitoring treatment – administration, safety and adverse event management and reporting; data collection and interpretation

SUCCESSOR-1 - A Phase III, Two-Stage, Randomized Study of Mezigdomide, Bortezomib, and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Relapsed/ Refractory Multiple Myeloma (RRMM)

Co-investigator

Supervising patient recruitment, enrollment, and informed consent processes; monitoring treatment – administration, safety and adverse event management and reporting; data collection and interpretation

Training courses and educational symposia

LaCantera Masterclass on the role of bone marrow transplantation in lymphomas 2024
Hematology Masterclass 2018 Budapest, Hungary
Multiple Myeloma Medical Tutorials 2018, Oxford, UK
North East Europe Multiple Myeloma Expert Forum Meeting 2018, Bucharest, Romania
Summer school for young hematologists, 2017, Bucharest, Romania
Palliative care in oncology, 2017, Bucharest, Romania

Honors and Awards

2024: Sommer Scholar Johns Hopkins Bloomberg School of Public Health
2023: Clinical Research Training in Hematology (EHA)
2021: ASH Abstract Achievement Award
2019: Visitors Training Program- American Society of Hematology
2016 : Ranked 4th /807 in Medical School
2014 : Erasmus Scholarship for 6 months at Universita di Bologna, Scuola di Medicina e Chirurgia (Italy)

Summer Internships

2015: Summer Internship at the Romanian Government, Health Ministry
2014: International Federation of Medical Students Associations- Summer Internship in Thoracic Surgery, Trieste, Italy
2014: Member of the Romanian Delegation at the XVIIth General Assembly of the International Medical Students Association Taipei, Taiwan
2013 International Federation of Medical Students Associations -Summer Internship in Thoracic Surgery, Tunis, Tunisia
2012 International Federation of Medical Students Associations -Summer Internship in Plastic Surgery, Skopje, Macedonia

Publications

Histone Deacetylase Inhibitors for Peripheral T-Cell Lymphomas.
Irimia R, Piccaluga PP.
Cancers (Basel). 2024 Sep 30;16(19):3359. doi: 10.3390/cancers16193359. PMID: 39409979; PMCID: PMC11482620.

Determining diagnostic delays in Romanian multiple myeloma patients using the Aarhus statement.
Irimia R, Badelita S, Barbu S, Cirlan IL, Zidaru IL and Coriu D
Front. Med. 11:1372907. doi: 10.3389/fmed.2024.1372907

Efficacy of Carfilzomib Treatment in Bortezomib-Refractory Patients-Real Life Experience in a Tertiary Romanian Hospital.

Irimia R, Badelita SN, Barbu S, Zidaru L, Carlan IL, Coriu D.

The J Clin Med. 2024 Apr 9;13(8):2171. doi: 10.3390/jcm13082171. PMID: 38673444; PMCID: PMC11050610.

CD38 is a key regulator of tumor growth by modulating the metabolic signature of malignant plasma cells

Ruxandra Irimia, Margo Gerke, Maya Thakar, Zhihong Ren, Eric Helmenstine, Philip Imus, Gabriel Ghiaur, Robert Leone, Christian B. Gocke

American Society of Hematology Conference 2021, Atlanta, USA, Poster Presentation

Evans Syndrome as a Possible Complication of Brentuximab Vedotin Therapy for Peripheral T Cell Lymphoma

Irimia R, Barbu S, Popa C, Badelita S.

Hematol Rep. 2023 Mar 22;15(1):220-224. doi: 10.3390/hematolrep15010023. PMID: 36975736; PMCID: PMC10048708.

Muscle involvement with pseudohypertrophy in systemic light chain amyloidosis: case report

Mirela Draghici, Andreea Jercan, Sorina Nicoleta Badelita, Ruxandra Maria Irimia, Monica Popescu, Alexandra Eugenia Bastian, Daniel Coriu

Medicine. 2021;100:51(e28267)

Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative Study

Rosanne Janssens , Tamika Lang , Ana Vallejo , Jayne Galinsky , Ananda Plate , Kate Morgan , Elena Cabezudo , Raija Silvennoinen , Daniel Coriu , Sorina Badelita , Ruxandra Irimia , Minna Anttonen , Riikka-Leena Manninen , Elise Schoefs , Martina Vandebroek , Anneleen Vanhellemont , Michel Delforge , Hilde Stevens , Steven Simoens , Isabelle Huys

Frontiers in Medicine, ISSN 2296-858X, 2021

Quercetin, Menadione, Doxorubicin combination as a potential alternative to Doxorubicin monotherapy of acute lymphoblastic leukemia. R. Irimia , I.T.Tofolean, R. Sandu, O.E.Baran, M.C.Ceausescu, V. Cosoreanu, M.T. Ilie, R. Babes, C. Ganea , I. Baran

DOCUMENTA HAEMATOLOGICA, Edit.DE GRUYTER OPEN; ISSN 1582-196X, 2016

Antiproliferative effect of doxorubicin/quercetin/menadione combination in leukemia Jurkat T cells.

O.E Baran, I.T. Tofolean, R. Irimia, I. Baran, C. Ganea.

Poster, 10th EBSA European Biophysics Congress, 18-22 July 2015, Dresda, Germania. Late Abstract Booklet p. 44

Green tea derived EGCG and vitamin K3: a synergic antiproliferative effect in acute lymphoblastic leukemia.

R. Irimia, I. Baran.

MEDICALIS International Congress for Medical Students and Young Professionals, 14-17 May 2015, Cluj-Napoca

Novel insights into the antiproliferative effect of quercetin, menadione and rotenone in human leukemia Jurkat T cells,

I. Baran, D. Ionescu, A. Filippi, M.M. Mocanu, A. Iftime, R. Babes, I.T. Tofolean, R. Irimia, A. Goicea, V. Popescu, A. Dimancea, A. Neagu, C. Ganea, LEUKEMIA RESEARCH, 2014, Volume: 38 Issue: 7 Pages: 836-849 Published: JUL 2014 (IF 2.692) (is. 0.950)

Doxorubicin induces G2/M arrest, Ca²⁺ release, oxidative stress and apoptosis in human leukemia Jurkat cells at clinical doses and dose rates, poster,

R.G. Sandu, I. Baran, D. Ionescu, A. Filippi, R. Babes, A. Goicea, A. Garaiman, R. Irimia, A. Dimancea, M. Gaman, C. Ganea, A. Murgoci. FEBS EMBO 2014 Congress, Paris, France

Mitochondrial respiratory Complex I probed by delayed luminescence spectroscopy,

I. Baran, D. Ionescu, S. Privitera, A. Scordino, M.M. Mocanu, F. Musumeci, R. Grasso, M. Gulino, A. Iftime, I.T. Tofolean, A. Garaiman, A. Goicea, R. Irimia, A. Dimancea, C. Ganea, JOURNAL OF BIOMEDICAL OPTICS, 2013, 18 (12), 127006, DOI: 10.1117/1.JBO.18.12.127006, (IF 2.752) (is. 1.910)

Quercetin exerts its antitumoral effect while manifesting a strong antioxidant character,

D. Ionescu, C. Ganea, A. Iftime, I.T. Tofolean, R. Irimia, A. Goicea, A. Dimancea, A. Neagu, I. Baran,

9th European Biophysics Congress - EBSA 2013, Lisbon, Portugal, Abstract Booklet, Eur. Biophys. J., (2013), P52, 42: S35=S208, S48, 2013

Conferences and workshops attended

EHA Meeting 2023, Frankfurt, Germany

EHA Meeting 2022, Vienna, Austria

ASH Meeting 2021, Atlanta, Georgia

ASH Meeting 2019, Orlando, Florida

Professional membership

Romanian Hematology Association

European Hematology Association – YoungEHA committee member

European Hematology Association – Education committee member

General Medical Council-Romania

General Medical Council- United Kingdom

Laboratory skills

Cell Culture: Cell line culture and maintenance, Cell-based assays, Seahorse assay

Flow cytometry

Molecular Biology Techniques: (DNA and RNA extraction, Polymerase Chain Reaction (PCR), Gel electrophoresis, Gene editing (CRISPR/Cas9))

Data Analysis: Relevant software (GraphPad Prism, DataTab), Statistics and data interpretation

Lab Safety

Lab Management

Scientific writing: Manuscript preparation, Grant proposal writing, Lab reports and documentation

Languages

Romanian: Native

English: C2

Italian: B2

French: A1

22 ianuarie 2025